Latest Medical Technology News

Echo IQ has secured a $1.26 million refund under the Australian Government's R&D Tax Incentive, reinforcing its commitment to AI-driven solutions for structural heart disease detection.

Micro-X Limited's trading suspension has been lifted following its announcement of an equity raising, signaling renewed market activity for the medical technology firm.

Cleo Diagnostics has responded to an ASX price query following a notable rise in its share price and trading volume, underscoring its patented ovarian cancer detection technology and ongoing U.S. clinical trials.

ImpediMed Limited has locked in a US$15 million growth capital facility with SWK Funding LLC, providing crucial financial flexibility to advance its SOZO Digital Health Platform and commercial ambitions.

Optiscan Imaging has initiated a pivotal pre-clinical gastrointestinal study in Germany using its first flexible prototype, aiming to revolutionize real-time GI tract imaging and diagnostics.

Echo IQ confirms the material significance of its pre-submission FDA meeting for EchoSolv HF, marking a pivotal step toward US market entry and commercialisation.

Nova Eye Medical has completed a $6.6 million placement to fund growth initiatives, supported by strong global sales growth and a major shareholder commitment. The capital raise aims to bolster sales teams and product development as the company targets profitability in its glaucoma division.

Nova Eye Medical reports a robust 39% increase in global sales driven by strong U.S. market demand and secures $6.6 million in fresh capital to fuel expansion and product development.

Uscom Limited reports a 56% increase in cash on hand to $2.17 million for Q2 2024, driven by strategic moves in China and new product regulatory approvals.

Optiscan Imaging Ltd reported a productive December quarter, marked by key product developments, strategic partnerships, and a stronger cash position, setting the stage for growth in medical and veterinary imaging markets.

ImpediMed Limited has reported record quarterly revenue and cash receipts for Q2 FY25, alongside significant growth in reimbursement coverage and a robust sales pipeline, signaling strong momentum in its digital health platform business.

Optiscan Imaging Ltd has secured a $1.775 million R&D tax refund for FY24, more than doubling last year’s amount thanks to expanded claims on overseas research. The boost will fund ongoing development of its cutting-edge confocal laser endomicroscopy technology.